ATE513551T1 - Zusammensetzungen und verfahren zur wiederherstellung der bakterienflora - Google Patents

Zusammensetzungen und verfahren zur wiederherstellung der bakterienflora

Info

Publication number
ATE513551T1
ATE513551T1 AT04704822T AT04704822T ATE513551T1 AT E513551 T1 ATE513551 T1 AT E513551T1 AT 04704822 T AT04704822 T AT 04704822T AT 04704822 T AT04704822 T AT 04704822T AT E513551 T1 ATE513551 T1 AT E513551T1
Authority
AT
Austria
Prior art keywords
compositions
methods
bacterial flora
subject
restoring
Prior art date
Application number
AT04704822T
Other languages
English (en)
Inventor
Pamela Drake
Jessie Stopsen
Original Assignee
Flora Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flora Technology Inc filed Critical Flora Technology Inc
Application granted granted Critical
Publication of ATE513551T1 publication Critical patent/ATE513551T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
AT04704822T 2003-01-24 2004-01-23 Zusammensetzungen und verfahren zur wiederherstellung der bakterienflora ATE513551T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44223803P 2003-01-24 2003-01-24
PCT/US2004/001775 WO2004067013A1 (en) 2003-01-24 2004-01-23 Compositions and methods for restoring bacterial flora

Publications (1)

Publication Number Publication Date
ATE513551T1 true ATE513551T1 (de) 2011-07-15

Family

ID=32825190

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04704822T ATE513551T1 (de) 2003-01-24 2004-01-23 Zusammensetzungen und verfahren zur wiederherstellung der bakterienflora

Country Status (4)

Country Link
US (2) US20040265291A1 (de)
EP (1) EP1596872B1 (de)
AT (1) ATE513551T1 (de)
WO (1) WO2004067013A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7029702B2 (en) 1998-07-07 2006-04-18 Ritter Natural Sciences Llc Method for increasing lactose tolerance in mammals exhibiting lactose intolerance
GB0505229D0 (en) * 2005-03-15 2005-04-20 Novexin Ltd Methods for stabilising, protecting, solubilising and folding proteins
DE102004025869A1 (de) * 2004-05-27 2005-12-22 Süd-Chemie AG Bioprotektivum
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
WO2006012536A2 (en) 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
WO2006097949A1 (en) * 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
WO2007033082A2 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Compositions comprising dimethyl sulfoxide (dmso)
US8435224B2 (en) 2005-09-12 2013-05-07 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (DMSO) and related compounds
AU2006291134C1 (en) 2005-09-12 2013-08-15 Abela Pharmaceuticals, Inc. Systems for removing dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same
US8480797B2 (en) 2005-09-12 2013-07-09 Abela Pharmaceuticals, Inc. Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
EP1776877A1 (de) 2005-10-21 2007-04-25 N.V. Nutricia Methode zur Förderung der Darmflora
AU2007260074B2 (en) * 2006-06-13 2011-12-08 Nestec S.A. Prevention and treatment of otitis media with non-pathogenic bacterial strains
AU2008201950A1 (en) * 2007-05-02 2008-11-20 Sociedad De Biotecnologias Antofagasta Limitada Kit and method to perform a biological test designed to evaluate minerals potential for being bioleached
WO2009092810A2 (en) * 2008-01-24 2009-07-30 Bacterfield Oü Single pharmaceutical composition containing antibiotics and probiotics
US9603876B2 (en) * 2008-09-25 2017-03-28 New York University Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment
BRPI0921494A2 (pt) 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
EP2400839B1 (de) 2009-02-24 2016-09-07 Ritter Pharmaceuticals, Inc. Präbiotische formulierungen und verwendungsverfahren dafür
US9839609B2 (en) 2009-10-30 2017-12-12 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) formulations to treat osteoarthritis
AU2010313228B2 (en) 2009-10-30 2014-05-29 Biogenic Innovations, Llc Methylsulfonylmethane (MSM) for treatment of drug resistant microorganisms
DK3564357T3 (da) 2010-02-01 2022-06-20 Rebiotix Inc Bakterieterapi mod clostridium difficile colitis
EP3202406A1 (de) 2010-04-28 2017-08-09 Ritter Pharmaceuticals, Inc. Präbiotische formulierungen und deren verwendungen
US8951512B2 (en) 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
US9386793B2 (en) 2010-08-20 2016-07-12 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
US9011909B2 (en) 2010-09-03 2015-04-21 Wisconsin Pharmacal Company, Llc Prebiotic suppositories
BR112013017013A2 (pt) * 2010-12-29 2016-10-25 Nestec Sa fibra e probiótico para a redução dos sintomas intestinais relacionados com o estresse crônico
US20130280225A1 (en) * 2010-12-29 2013-10-24 Nestec S.A. Fiber and probiotics for reducing intestinal symptoms related to stress
US20150079039A1 (en) 2012-04-13 2015-03-19 The Regents Of The University Of California Sinusitis diagnostics and treatments
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
KR102099503B1 (ko) 2013-06-05 2020-04-09 리바이오틱스, 인코퍼레이티드 미생물상 복원 요법(mrt) 조성물
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
KR101677516B1 (ko) * 2014-10-14 2016-11-18 대한민국 락토바실러스 루테리 블랙8, 및 이를 함유하는 항종양 조성물
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
ES2889902T3 (es) 2015-06-09 2022-01-14 Rebiotix Inc Métodos de fabricación de composiciones para terapia de restauración de la microbiota (TRM)
US10653728B2 (en) 2016-10-17 2020-05-19 New York University Probiotic compositions for improving metabolism and immunity
CN107373036A (zh) * 2017-09-04 2017-11-24 紫金县绿羽农业发展有限公司 一种复合微生态饲料添加剂的制备及应用
KR102268128B1 (ko) * 2021-02-09 2021-06-22 주식회사 락토메이슨 모유 유래 신규한 락토바실러스 루테리 lm1071 균주, 및 상기 균주 또는 이의 배양물을 포함하는 월경전 증후군 완화용 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3689640A (en) * 1967-09-28 1972-09-05 Univ Of Nebraska The Antibiotic acidophilin and process of preparing the same
US3852454A (en) * 1973-06-15 1974-12-03 Merck & Co Inc Treatment of rheumatoid arthritis
US3897307A (en) * 1974-10-23 1975-07-29 Hansens Lab Inc Stabilized dry cultures of lactic acid-producing bacteria
GB2122892B (en) * 1982-07-02 1986-01-29 Squibb & Sons Inc Nystantin pastille formulation
US4592748A (en) * 1984-05-18 1986-06-03 Vortex Research Corp. Yoghurt based douche kit and assembly therefor
JPS6314665A (ja) * 1986-07-07 1988-01-21 Zenkoku Nogyo Kyodo Kumiai Rengokai 繁殖雌豚飼育用飼料及びそれを用いて繁殖雌豚を飼育する方法
JP2806522B2 (ja) * 1987-09-04 1998-09-30 日本食品化工株式会社 分岐フラクトオリゴ糖の製造方法
US4986985A (en) * 1987-11-02 1991-01-22 Bar Ilan University Method of treating skin virus infections
US5236697A (en) * 1990-10-18 1993-08-17 Schrauzer Gerhard N Product for treatment of acne and other skin conditions
US5518740A (en) * 1990-12-13 1996-05-21 Innovative Freeze-Drying Products (Ifdp) N.V. Process for the preparation of yogurt based freeze-dried foodstuffs having a solid shape, and products obtained by said process
US5792451A (en) * 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5531989A (en) * 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
US5580579A (en) * 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
AU1854297A (en) * 1996-02-14 1997-09-02 Procter & Gamble Company, The Urogenital and intestinal disorder compositions comprising substance derived from plant species of the ericaceae family and a lactic acid bacteria growth factor
CA2269806C (en) * 1996-10-28 2006-01-24 Bernhard H. Van Lengerich Embedding and encapsulation of controlled release particles
US5837254A (en) * 1996-11-14 1998-11-17 Chen; Yu Method of treating candida and cryptococcus fungal infections by administering gentian
US6645506B1 (en) * 1997-04-18 2003-11-11 Ganeden Biotech, Inc. Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil
JPH10330267A (ja) * 1997-05-28 1998-12-15 Meiji Seika Kaisha Ltd ベロ毒素中和剤
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
EP1212093B1 (de) * 1999-08-26 2004-07-07 Ganeden Biotech, Inc. Verwendung von emu-öl als träger für fungizide, antibakterielle und antivirale arzneien
GB2369777B (en) * 2000-10-05 2004-10-27 St Ivel Ltd Food products with antimicrobial lactic acid bacteria

Also Published As

Publication number Publication date
WO2004067013A1 (en) 2004-08-12
EP1596872B1 (de) 2011-06-22
US20100189702A1 (en) 2010-07-29
EP1596872A1 (de) 2005-11-23
US20040265291A1 (en) 2004-12-30

Similar Documents

Publication Publication Date Title
ATE513551T1 (de) Zusammensetzungen und verfahren zur wiederherstellung der bakterienflora
IN2014DN06610A (de)
ZA202302150B (en) Identification of agriculturally beneficial microbial compositions and uses thereof
WO2007130655A3 (en) Phage derived antimicrobial activities
MX2022015587A (es) Composiciones y métodos para promover la salud de las plantas.
DE602005012276D1 (de) Verwendung von probiotischen bakterien zur herstellung von topischen zusammensetzungen zum schutz der haut
BR112013005426A2 (pt) "composto, composição, formulação farmacêutica, métodos para inibir uma enzima, para matar e/ou prevenir o crescimento de um micro-organismo, para tratar e/ou prevenir uma doença em um animal, e para inibir o domínio de edição de uma sintetase de t-rna, e, uso de um composto ou uma de combinação."
DE60216614D1 (de) Zusammensetzung mit bakteriostatischen und bakteriziden eigenschaften gegen bakterielle sporen und zellen und verfahren zu deren verwendung zur behandlung von lebensmitteln
TW200744639A (en) Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
WO2006076009A3 (en) Transcription factor modulating compounds and methods of use thereof
WO2013102021A3 (en) LOW pH DISINFECTANT COMPOSITION
DE602004010540D1 (de) Stabile zusammensetzungen von sporen, bakterien und/oder pilzen
MXPA05009352A (es) Metodos y composiciones para tratamiento y prevencion de staphylococcus y otras infecciones bacterianas.
ATE499091T1 (de) Antimikrobielle materialien
WO2009102143A3 (ko) 김치유래 락토바실러스 플란타룸 bls41 및 그 용도
WO2008082692A3 (en) Isothiocyanate compounds, pharmaceutical compositions, and uses thereof
MX359743B (es) Compuestos antimicrobianos y métodos para fabricar y utilizar los mismos.
TW200734344A (en) Antibacterial agents
MX2024005796A (es) Aumento del rendimiento de agentes biologicos y reduccion de la variacion en las areas de aplicacion.
MX2025005724A (es) Composiciones y metodos microbianos
WO2008130368A3 (en) Transcription factor modulating compounds and methods of use thereof
EP3939599A3 (de) Silikathaltige zusammensetzungen und verfahren zur behandlung
WO2021035115A3 (en) Growing programmable enzyme-functionalized and sense-and-response bacterial cellulose living materials with engineered microbial co-cultures
PH12021552875A1 (en) METHODS AND COMPOSITIONS COMPRISING STAPHYLOCOCCUS PROTEIN A (SpA) VARIANTS
MX2023003089A (es) Formas farmaceuticas solidas de bacterias.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties